Blind World


Macular Degeneration.
nationwide Phase III clinical trial for age-related macular degeneration (AMD).





April 16, 2004.
The Foundation Fighting Blindness.




This provides information about a new, nationwide Phase III clinical trial for age-related macular degeneration (AMD) that is actively enrolling patients. The Foundation Fighting Blindness (FFB) is sharing this research news in case you or someone you know may be interested.


People with the "wet" form of age-related macular degeneration (AMD) in one eye and "dry" AMD in their other eye are at high risk for developing wet AMD in the other eye within 5 years.


This Phase III clinical trial is being conducted to evaluate the safety and effectiveness of the investigational drug Anecortave Acetate as a treatment to stop the progression of dry AMD to wet AMD. Alcon Research Ltd. is comparing this experimental drug to a "sham" procedure (no active study medication administered).


People eligible to participate in this clinical study must:
+ be 50 years or older
+ currently have (or previously had) wet AMD in one eye and have at-risk dry AMD that meets certain clinical characteristics in the other eye.


In addition to an initial screening visit, eligible subjects will visit an assigned eye doctor at one of the test centers twice a year for four years to receive study treatments and examinations. Subjects enrolled in the study will not know whether they are receiving Anecortave Acetate or the "sham" procedure, which imitates the procedure used to give patients the investigational drug.


During each of the required eight visits to the assigned eye doctor, patients will receive thorough, study-related eye exams and treatments at no cost to the patient.


For more information about this trial and eligibility requirements, visit Alcon's website at www.alcon.com/us/eo/clinicalstudies, or contact Alcon directly by:
Calling toll-free: 1-866-692-5959
E-mail: wetamd@inveresk.com


NOTE: FFB recommends consulting your own ophthalmologist before enrolling in any study.


FFB and Alcon make no representations or warranties as to the safety or the effectiveness of this experimental treatment for AMD. Alcon's clinical trial for this treatment must be completed and go through FDA approval to confirm the safety and efficacy of this experimental treatment.


The Foundation's mission is to drive research for the discovery of preventions, treatments and cures of retinal diseases, including macular degeneration. Educating patients and physicians on worthwhile clinical trials, such as this, enables us to help accelerate finding treatments and cures, ultimately to benefit millions of patients.


Certainly, you may forward this to others.




End of article.






Go to ...


Top of Page.

Previous Page.

List of Categories.

Home Page.





Blind World Website
Designed and Maintained by:
George Cassell
All Rights Reserved.



Copyright Notice
and Disclaimer.